10-Q quarterly report · filed Nov 10, 2026

Arbutus Biopharma Corp (ABUS) Q3 2026 10-Q Quarterly Report

Short answer

Arbutus Biopharma Corp (ABUS) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $299,000 (down 43.5% year over year) with net income of $59M.

Q3 2026 key financials · XBRL

Revenue
$299,000
−43.5% YoY · −70.5% QoQ
Net income
$59M
+863.6% YoY · +1249.4% QoQ
Operating margin
-3509.7%
EPS (diluted)
$0.29
+825.0% YoY · +1066.7% QoQ

Source: XBRL data from the Arbutus Biopharma Corp (ABUS) Q3 2026 10-Q on SEC EDGAR. USD.

Arbutus Biopharma Corp Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $13.0M, down $0.2M YoY, reflecting lower ONPATTRO royalty revenue
  • Q3 operating loss $10.5M vs $8.7M loss YoY, operating margin -80.5% vs -67.2%
  • Best program: IM-PROVE II, 53% (33/62) achieved functional cure or remained off NA therapy
  • Cash and equivalents $264.2M at September 30, up from $18.0M; operating cash flow $225.7M
  • Capital deployment: $230M share repurchase settled October 5; AB-101 development resumed after FDA clinical hold lifted

Risk Factors

  • No material changes from the December 31, 2025 Form 10-K risk factors
  • Carried-forward risks include clinical development and regulatory approval uncertainty
  • Carried-forward risks include dependence on partnered product candidates and licensing arrangements
  • Carried-forward risks include liquidity needs and potential financing requirements

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Arbutus Biopharma Corp quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.